CDER guidance agenda
This article was originally published in The Tan Sheet
Executive Summary
"Minimum Data Elements to be Included in a Serious Adverse Event Report for Monograph OTC Products" and "Labeling Dietary Supplements for Women Who Are or Could Be Pregnant," are two of 40 guidances the Center for Drug Evaluation and Research plans to develop during 2007. According to the March 19 1document, the agenda items are guidances "under development as of the date of this posting." Other guidances listed include: "Labeling of Over-the-Counter Skin Protectant Drug Products," "Drug Interaction Studies - Study Design, Data Analysis and Implications for Dosing and Labeling" and "Individual Product Bioequivalence Recommendations." Several of the guidances under development have previously been listed in annual guidance agendas, including "Labeling Dietary Supplements for Women Who Are or Could Be Pregnant," which has been listed since 2004...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.